CEO and Chairman
Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical Industries, Limited ("Teva") as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served on boards for Key Pharmaceuticals, Thalmann Financial Services, Continucare Corporation, TransEnterix, SafeStitch Medical, PROLOR Biotech, Sevion Therapuetics, Inc. and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange.
Dr. Frost currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and The Florida Council of 100 and as a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He was also a member of the Board of Trustees of the Scripps Research Institute until November 2012.
Dr. Frost is a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.
CTO and Vice Chairman
Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer at OPKO since May 2007 and as a director since February 2007. Previously, Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical, and Neovasc, Inc.
Dr. Hsiao has served since 2008 as Chairman of the Board of Non-Invasive Monitoring Systems, Inc., a medical device company and was named Interim CEO of the company in 2012. Dr. Hsiao is also a director of TransEnterix, Inc., a medical device company, and Cocrystal Pharma, Inc.
Executive Vice President, Administration
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a director since February 2007. Previously, Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.
Mr. Rubin currently serves on the board of directors of Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, Inc., a medical device company; Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses; ChromaDex Corp., a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, Inc. a company developing and marketing medical specialty vascular devices, and Red Violet, Inc., leading analytics and information solutions provider.
Mr. Rubin previously served as a director of Castle Brands, Inc., Dreams, Inc., Safestitch Medical, Inc., Cogent, Inc., PROLOR Biotech, Inc., BioCardia, Inc., and VBI Vaccines, Inc.
Senior Vice President and CFO
Mr. Logal has served as OPKO's Sr. Vice President and Chief Financial Officer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012.
Previously, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves as chairman of the board of directors of Xenetics Biosciences, Inc., a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc.
Jon R. Cohen
Senior Vice President, OPKO Health; Executive Chairman, BioReference Laboratories
As Executive Chairman, Dr. Cohen has overall responsibility for Bioreference Laboratory and GeneDx. BioReference is one of the largest clinical laboratories in the United States. Dr. Cohen has more than 30 years of healthcare experience as a seasoned strategic leader with extensive P/L and operational responsibility and a successful track record of growing existing business and developing new business ventures. Previously, Dr. Cohen served for over nine years as a Senior Executive and named executive officer at Quest Diagnostics. Originally as Chief Medical Officer, most recently as Senior Vice President and Group Executive - Diagnostic Solutions. His business responsibilities during his tenure included the hospital reference business, cancer services, pathology services, sports diagnostics, and professional lab services, Quest's comprehensive offerings to hospitals and health systems.
Before joining Quest, Dr. Cohen served Senior Advisor to New York Governor David A. Paterson responsible for all strategy and planning after having run for Lieutenant Governor of New York in 2006 on a platform of healthcare reform. For seven years he served as Chief Medical Officer at North Shore-Long Island Jewish Health System (Northwell Health). In 2010, he was named one of the nation's top 50 most powerful physician executives by Modern Healthcare. His 2012 TEDMED, "Why Don't Patients Act Like Consumers?" was recently ranked the # 1 TEDMED talk that every healthcare executive needs to watch.
A vascular surgeon, he completed his residency in surgery at New York Presbyterian Hospital/Weill Cornell Medical Center and fellowship at the Brigham and Women's Hospital at Harvard Medical School.
President, BioReference Laboratories
Mr. Monk joined BioReference Laboratories in May 2018 as General Manager. In January 2019 he was promoted to President in recognition of the significant progress made in achieving greater operational efficiency to position BioReference for profitable growth. In the role of President, he has Operational Responsibility for all Commercial, Service, Laboratory and Support functions at BioReference and GeneDx.
Previously, Mr. Monk served as Vice President of Operations for the East Region at Quest Diagnostics Inc following a spell as Managing Director for their New York / New Jersey region where he had full P&L responsibility. Earlier in his Health Care career, he served as Vice President Global Engineering and Vice President Operations for NJ / Puerto Rico at Schering -Plough where he was responsible for the manufacture of all Claritin, Nasonex and Asmanex brands. Prior to this, he held positions of increasing responsibility for GlaxoWellcome including engineering and operations culminating in leading the Wellcome site at Dartford, UK. He is an engineer by training and has led teams to create facilities in many countries including Japan, Singapore, Brazil, and most European nations. His guiding principles are to follow the path of continuous improvement to operational excellence and that there is an optimal solution for every problem. He received his MA in Engineering from the University of Cambridge, UK and became a Chartered Engineer through the Institute of Mechanical Engineers.
CEO of OPKO Renal
Dr. Bishop has served as CEO of the OPKO Renal Division since it was formed from OPKO's acquisition of Cytochroma Inc. on March 4, 2013. Dr. Bishop had served as President & CEO of Cytochroma since June 2006, bringing a wealth of management experience in the pharmaceutical industry across multiple disciplines including Research & Development, Regulatory Affairs, Operations, and Business Development. Dr. Bishop co-founded Proventiv Therapeutics, LLC in September 2005 where he served as President. Proventiv Therapeutics, LLC, and its lead drug, CTAP101 Capsules (approved by FDA in 2016 as "Rayaldee® (calcifediol)", were acquired by Cytochroma in June 2006. From September 1987 to June 2005, Dr. Bishop held various senior management positions at Bone Care International, Inc. (NASDAQ: BCII), a public specialty pharmaceutical company focused on developing and commercializing vitamin D hormone therapies. Dr. Bishop's positions with Bone Care included President, CEO, Director, Executive Vice President of Research and Development, and Chief Scientific Officer. He was the first full-time employee in Bone Care, and he ran the Company from its inception until after the commercial launches of its first two products. Under Dr. Bishop's direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for secondary hyperparathyroidism (SHPT), metabolic bone disease, psoriasis and cancers of the prostate, breast, and colon. Dr. Bishop was responsible for the successful preparation and prosecution of three new drug applications that ultimately led to U.S. marketing approvals for a novel vitamin D drug, named doxercalciferol, for SHPT in dialysis patients (Hectorol® 2.5 mcg Capsules and Hectorol® Injection) and pre-dialysis patients (Hectorol® 0.5 mcg Capsules). Bone Care was acquired for $720 million by Genzyme Corporation in July 2005. Before joining Bone Care, Dr. Bishop held various management positions in the Health Care Division of the Procter & Gamble Company. Dr. Bishop completed a four-year National Institutes of Health Postdoctoral Fellowship in vitamin D Biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in Nutritional Biochemistry from Virginia Tech, after earning an undergraduate degree in Chemistry from the University of Virginia.
President of Transition Therapeutics
Dr. Cruz joined OPKO Health, Inc. in June 2017 as CEO, Transition Therapeutics Corp., ULC. Dr. Cruz was one of the founders and served as the Chairman and Chief Executive Officer of Transition Therapeutics, a NASDAQ and TSX publicly traded company. Transition's lead development programs are an oral compound for the treatment of Alzheimer' s disease for agitation and aggression and a GLP1 dual agonist for the treatment of type 2 diabetes partnered with Eli Lilly. Dr. Cruz was Co-founder of Angiotech Pharmaceuticals Inc. which developed the Taxol-coated stent for cardiovascular restenosis marketed by Boston Scientific. He served as Vice-President of Research and as a member of the Board of Directors. Dr. Cruz was a founding member and served as the Scientific Director and CEO of the Canadian Arthritis Network (CAN), a Network Centers of Excellence. Under his leadership, CAN raised approximately 30 Million dollars to support funding of research in the Network. Dr. Cruz has established numerous partnerships with Big Pharma, Biotech companies and the investment community in the Biotech Sector over the last 25 years. Dr. Cruz had a successful academic career from 1987 to 2008 with over 150 publications. He was a senior scientist at Mount Sinai Hospital and a Professor at the University of Toronto until 2008.
President, OPKO Health Iberoamerica
Hans Berner has been with OPKO since 2009. Since April of 2018, Hans has served as the President of OPKO Health Iberoamerica, which encompasses six business units located in five countries: Brazil, Chile, Mexico, Spain, and Uruguay. Hans has extensive experience in the Latin American pharmaceutical industry previously overseeing operations in Argentina, Mexico, and Uruguay as Corporative General Manager of Laboratorios ELEA S.A. Additionally, Hans worked as both the Latin American Regional Director for the IVAX Corporation and the General Manager of IVAX Argentina and IVAX Uruguay. Hans also has a background in business development and finance serving as Business Development Manager at Laboratorio Chile S.A. and Finance Manager at ING Bank Chile.
With over 15 years of teaching experience at various universities, Hans now holds a Professorship at the Pontificia Universidad Católica de Chile instructing MBA students in the subjects of Competitive Strategy and M&A.
Hans earned his Commercial Engineering degree from the Universidad de Santiago de Chile before earning his MBA from the Business School of Pontificia Universidad Católica Argentina. Subsequently, Hans entered post-graduate studies at Babson College in Entrepreneurship (Educators Santander Fellows).
Kate Inman joined OPKO Health Inc. (Nasdaq: OPK) in 2007 and was named OPKO's General Counsel in 2014. She oversees legal and compliance matters for OPKO's global operations, which includes pharmaceutical, diagnostics, and laboratory businesses. Prior to joining OPKO, Kate practiced in the areas of general corporate, securities, and mergers and acquisitions with Holland & Knight in Miami. She also served as a law clerk to the Honorable Edward B. Davis, Chief Judge for the United States District Court for the Southern District of Florida, and for the Honorable Peter T. Fay, United States Court of Appeals, Eleventh Circuit.
Jane Pine Wood
CLO, BioReference Laboratories
Jane Pine Wood is a licensed and practicing attorney who oversees the company's Legal Department, with a focus on legal and regulatory compliance, corporate governance and corporate ethics. Jane joined BioReference after serving nearly three decades in private practice at McDonald Hopkins, LLC. She is a member of the American Health Lawyers Association, and has received the Association of Pathology Chairs' Friends of Pathology Award, American Society of Clinical Pathology Patients' Advocate Award, and is listed among Massachusetts Super Lawyers - Top 50 Female Lawyer Award. She holds her J.D. from Vanderbilt University School of Law and B.A. in History from Texas A&M University.
CEO, Eirgen Pharma
Damien Burke is the CEO of EirGen Pharma, a Waterford based pharmaceutical company specializing in the development and commercial supply of high potency pharmaceutical products including a number of oncology products. Damien has over 20 years of experience in the pharmaceutical industry and has held a number of senior leadership positions in supply chain, operations and business development. He has a MSc. in Supply Chain and Operational management from the University of Liverpool. Established in 2006, EirGen has grown rapidly and now exports products to over 40 countries worldwide including all of EU, U.S., Canada, Japan from its state of the art high containment facility. The facility is licensed by the Irish HPRA, FDA, and Japanese PMDA regulatory authorities.
President of API
Before joining OPKO, L. Arie Gutman founded FineTech Pharmaceuticals in 1990 which engaged in the development, manufacture, and marketing of specialty active pharmaceutical ingredients (APIs). Before its acquisition by OPKO in 2011, Finetech was previously acquired by Par Pharmaceuticals in 2002. Arie was then chosen to sit on the executive board. Arie also served as a Professor of Organic Chemistry at Technion - Israel Institute of Technology from 1992-2003, where he was recognized for his excellence in teaching and has been a Fellow of Churchill College, Cambridge since 1987. Arie has authored numerous publications and filed dozens of patents for his work. Arie earned his bachelors from Hebrew University, his M.Sc. from Technion - Israel Institute of Technology and his Ph.D. from Cambridge University.
National Sales Director, OPKO Renal
Ms. Sandler joined OPKO Health in July, 2019 as the National Sales Director for the Renal Division. Ms. Sandler brings over 25 years of sales and marketing experience to OPKO along with a robust track record of success across numerous roles in the pharmaceutical industry. Before joining OPKO, Ms. Sandler most recently served as regional Field Vice President for GlaxoSmithKline. During her career, Ms. Sandler has led multiple product launches, including the first commercial product launch for Omeros Corporation, a Seattle based biotech company. Prior to Omeros, Ms. Sandler served several other prominent pharmaceutical companies, including Sunovion Pharmaceuticals, Inc., Johnson & Johnson and Pfizer Inc. across a wide range of therapeutic categories, developing a broad skill set pertinent to all stages of brand development.